Hepatocyte growth factor attenuates pancreatic damage in caerulein-induced pancreatitis in rats.
Hepatocyte growth factor (HGF) overexpression was reported in experimental and clinical acute pancreatitis. These observations prompted us to determine the effect of HGF administration on the development of caerulein-induced pancreatitis in rats. Acute pancreatitis was induced by s.c. infusion of caerulein (10 microg/kg/h) for 5 h. HGF was administrated twice (30 min before caerulein or saline infusion and 3 h later) at the doses: 0.4, 2, 10 or 50 microg/kg s.c. Immediately after cessation of caerulein or saline infusion, the pancreatic blood flow, plasma amylase and lipase activity, plasma cytokines concentration, cell proliferation, and morphological signs of pancreatitis were examined. Caerulein administration induced acute edematous pancreatitis manifested by 41% decrease in DNA synthesis, 53% inhibition of pancreatic blood flow, a significant increase in plasma amylase and lipase activity, plasma interleukin-1beta and interleukin-6 concentration, as well as, the development of the histological signs of pancreatic damage (edema, leukocyte infiltration, and vacuolization). Administration of HGF without induction of pancreatitis increased plasma interleukin-10. Treatment with HGF, during induction of pancreatitis, increased plasma interleukin-10 and attenuated the pancreatic damage, what was manifested by histological improvement of pancreatic integrity, the partial reversion of the drop in DNA synthesis and pancreatic blood flow, and the reduction in pancreatitis evoked increase in plasma amylase, lipase, and interleukin-1beta and interleukin-6 levels. HGF administrated at the dose 2 microg/kg exhibited a similar beneficial effect as administration of HGF at the doses 10 or 50 microg/kg. Treatment with HGF at the dose 0.4 microg/kg was less effective. We conclude that: (1) administration of HGF attenuates pancreatic damage in caerulein-induced pancreatitis; (2) this effect seems to be related to the increase in production of interleukin-10, the reduction in release of interleukin-1beta and interleukin-6, and the improvement of pancreatic blood flow.
Warzecha
Z
Z
Department of Physiology, Jagiellonian University Medical School, 16 Grzegórzecka Street, 31-531, Cracow, Poland.
Dembiński
A
A
Konturek
P C
PC
Ceranowicz
P
P
Konturek
S J
SJ
Tomaszewska
R
R
Schuppan
D
D
Stachura
J
J
Nakamura
T
T
D000681:Amylases / Q000097:blood; D000818:Animals; D002108:Ceruletide / Q000037:antagonists & inhibitors; D004195:Disease Models, Animal; D017228:Hepatocyte Growth Factor / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D015850:Interleukin-6 / Q000097:blood; D008049:Lipase / Q000097:blood; D008297:Male; D010179:Pancreas / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D010195:Pancreatitis / Q000097:blood / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow; D013997:Time Factors
D015850:Interleukin-6; D017228:Hepatocyte Growth Factor; D002108:Ceruletide; D008049:Lipase; D000681:Amylases